Funding for this research was provided by:
Hjärt-Lungfonden
Anna-Lisa och Bror Björnssons Stiftelse
Region Skåne
Skånes universitetssjukhus
Vetenskapsrådet
Lund University
Article History
Received: 21 January 2022
Accepted: 24 March 2022
First Online: 9 April 2022
Declarations
:
: Dr. Einar Heiberg founded the company Medviso AB, Lund, Sweden, and is the major shareholder of said company and although the software Segment is freely available for research the company also sells a CE-marked and FDA-approved version for commercial use. The remaining authors declare that they have no competing interests.
: The regional Ethics Review Board (Lund, Sweden) approved the study.
: All participants and their guardians when appropriate provided written informed consent before participation in the study.
: Not applicable.